Vesugen

Vesugen, also indexed as Vezugen in parts of the literature, is a short synthetic tripeptide studied mainly in Russian gerontology and vascular biology publications. The defensible evidence base is small and uneven: one small human clinical report evaluated Vezugen in older patients with vascular disease contexts, while supporting mechanistic work used vascular endothelial cell cultures and molecular docking. Another small human study compared Vesugen with Pinealon in older adults with chronic polymorbidity. Overall, the literature supports only cautious research-language statements around vascular and endothelial signaling, proliferation markers, and exploratory gerontology endpoints. Vesugen should not be presented as an established treatment for vascular disease, aging, erectile dysfunction, or neurologic conditions.

Vascular Research Context

Small clinical and gerontology reports evaluated Vesugen/Vezugen in vascular impairment contexts, but the designs are not strong enough for broad efficacy claims ^[1][3].

Endothelial Cell Mechanisms

Vesugen was associated with Ki-67-related proliferation markers and modeled interaction with the MKI67 promoter region in vascular endothelial cell work ^[2].

Evidence Boundary

The available sources support research context only and should not be translated into vascular, sexual-health, neurologic, or anti-aging treatment claims ^[1][2][3].

Small Human Evidence Base

Human safety evidence is limited to small, older, narrowly reported studies; no large randomized trials or modern regulatory labels were found ^[1][3].

Biological Signal Caveats

Gerontology work reported mixed cellular signals, so safety should not be inferred from peptide size or supplier claims ^[3].